Contribute Try STAT+ Today

A new year often means new prices for pharmaceuticals, and several companies have imposed price hikes just shy of 10 percent on numerous drugs, a move that appears designed to avoid withering scrutiny of companies that take double-digit increases.

One notable example is Allergan, which last year attempted to single-handedly staunch criticism of the pharmaceutical industry by issuing a “social contract” in which it promised to avoid “price gouging” and limit price hikes to single-digit percentage increases.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • May I observe under ‘the rule of 5’s,’ those increases count as 10 pct? Even the 9.5 percent one? Not that anyone will care of course…..

    • I would have much preferred 9.9999 percent. As any math student knows 9.9999 is a non-zero repeating infinitesimal that will never get to 10. Time for our critics to bone up on their irrationals.

Comments are closed.